Skip to main content
. 2015 Apr 20;10(4):e0124109. doi: 10.1371/journal.pone.0124109

Fig 3. In-clinic trough PEFR response for patients receiving tiotropium Respimat add-on or placebo Respimat add-on.

Fig 3

In-clinic trough PEFR response for patients receiving tiotropium Respimat or placebo Respimat as add-on to maintenance therapy of inhaled corticosteroids, with or without a long-acting β2-agonist, over the 52-week study period (full analysis set). Tiotropium Respimat and placebo Respimat dosed once-daily in the evening. Baseline mean (standard deviation) at visit 2 (randomisation), L/min: 371.0 (120.2). PEFR, peak expiratory flow rate.